Shattuck Labs

SHATTUCK LABS INC

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Levi Strauss

News

Pre-Market Outlook

Markets

Movers

AREB

BJDX

CHSN

CVRX

GLXG

GRFX

IPDN

IVDA

KNOP

KPTI

LEVI

PRSU

SOBR

STTK

SVRE

Levi sorprende al mercado con ganancias trimestrales mejores de lo esperado y una perspectiva 2025 que mantiene sin cambios.

Acciones de Levi Strauss suben un 10%; Aquí están 20 acciones que se mueven en el premercado de EE. UU.

Shattuck Labs Inc

Health Care

Press Releases

Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress

Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Earnings

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Annovis Bio

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

FibroGen

Generation Bio

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Lantern Pharma

LAVA Therapeutics

MAIA Biotechnology

Medicus Pharma

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

PepGen

Pluri

Propanc Biopharma

Plus Therapeutics

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Senti Biosciences

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

Exicure

XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock

Comments

Shattuck Labs

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL